Daniel Reed

Sheridan Reed is a seasoned regulatory intelligence and research and development professional in the pharmaceutical industry. Starting with a Bachelor of Science from the University of Liverpool, Sheridan went on to study a Master's degree and a Doctor of Philosophy (PhD) at Imperial College London, where she worked in cardiovascular medicine, stem cell therapy, biomarkers, diagnostics, and patient advocacy groups.

Sheridan has held multiple positions at AstraZeneca, currently serving as the Senior Director of Regulatory Intelligence in their Late CVRM branch. In this role, she provides leadership, portfolio, and product level support for global regulatory strategy. Her experience includes EMEA Team Lead - Head of Life Sciences Group at GLG, Competitive Intelligence Leader - Late Stage & Commercial CVRM at AstraZeneca, Business Insights Analyst at Silence Therapeutics plc, and Consultant, Senior Business Analyst, and Business Analyst at Lifescience Dynamics Limited.

Additionally, Sheridan served as an honorary fellow at IQVIA, a visiting scientist at the Medicines and Healthcare products Regulatory Agency, and an ambassador for Stem cells and personalized medicine at the Pulmonary Hypertension Association UK. She has also held a position with the Young Pharmacologist Advisory Group at the British Pharmacological Society.

Overall, Sheridan Reed's knowledge, experience, and skills demonstrate her expertise in regulatory affairs strategy for complex therapies, team leadership and people management, as well as research and development in cardiovascular medicine, stem cell therapy, and biomarkers.